Phosphoinositide 3-Kinases

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 78: Line 78:
**[[3hiz]], [[4jps]] - hTI-PI3K p110α (mutant) + p85α <br />
**[[3hiz]], [[4jps]] - hTI-PI3K p110α (mutant) + p85α <br />
**[[2rd0]], [[4l1b]] - hTI-PI3K p110α + p85α<br />
**[[2rd0]], [[4l1b]] - hTI-PI3K p110α + p85α<br />
-
**[[5sxk]], [[5sx8]], [[5sx9]], [[5sxa]], [[5sxb]], [[5sxc]], [[5sxd]], [[5sxe]], [[5sxf]], [[5sxi]], [[5sxj]], [[5sw8]], [[5swg]], [[5swo]], [[5swp]], [[5swr]], [[5swt]], [[5dxh]] - hTI-PI3K p110α + p85α + inhibitor<br />
+
**[[5sxk]], [[5sx8]], [[5sx9]], [[5sxa]], [[5sxb]], [[5sxc]], [[5sxd]], [[5sxe]], [[5sxf]], [[5sxi]], [[5sxj]], [[5sw8]], [[5swg]], [[5swo]], [[5swp]], [[5swr]], [[5swt]], [[5dxh]], [[5xgj]], [[5xgi]]], [[5xgh]] - hTI-PI3K p110α + p85α + inhibitor<br />
**[[5ul1]], [[5ukj]], [[5itd]], [[5fi4]], [[4zop]] - hTI-PI3K p110α (mutant) + p85α + inhibitor<br />
**[[5ul1]], [[5ukj]], [[5itd]], [[5fi4]], [[4zop]] - hTI-PI3K p110α (mutant) + p85α + inhibitor<br />
**[[5uk8]] - hTI-PI3K p110α (mutant) + p85α (mutant) + inhibitor<br />
**[[5uk8]] - hTI-PI3K p110α (mutant) + p85α (mutant) + inhibitor<br />
Line 91: Line 91:
**[[4tuu]], [[4tv3]] - hTI-PI3K p110α<br />
**[[4tuu]], [[4tv3]] - hTI-PI3K p110α<br />
**[[2enq]] - hTI-PI3K p110α C2 domain<br />
**[[2enq]] - hTI-PI3K p110α C2 domain<br />
-
**[[3zim]], [[4a55]], [[4oys]], [[4ph4]], [[4uwf]], [[4uwg]], [[4uwh]], [[4uwk]], [[4uwl]], [[5ubr]], [[5dxt]] - hTI-PI3K p110α + inhibitor<br />
+
**[[3zim]], [[4a55]], [[4oys]], [[4ph4]], [[4uwf]], [[4uwg]], [[4uwh]], [[4uwk]], [[4uwl]], [[5ubr]], [[5dxt]], [[4ykn]] - hTI-PI3K p110α + inhibitor<br />
*Type I PI3K p110β
*Type I PI3K p110β
Line 100: Line 100:
* Type I PI3K p110γ
* Type I PI3K p110γ
-
**[[3lj3]] – hTI-PI3K p110γ + pyrrolopyridine-benzofuran inhibitor <br />
+
**[[3lj3]], [[5oq4]], [[6c1s]] – hTI-PI3K p110γ + pyridine derivative inhibitor <br />
**[[3l54]] – hTI-PI3K p110γ + quinoline derivative <br />
**[[3l54]] – hTI-PI3K p110γ + quinoline derivative <br />
**[[3l08]] – hTI-PI3K p110γ + GSK2126458 <br />
**[[3l08]] – hTI-PI3K p110γ + GSK2126458 <br />
**[[3ibe]]– hTI-PI3K p110γ + pyrazolopyrimidine <br />
**[[3ibe]]– hTI-PI3K p110γ + pyrazolopyrimidine <br />
-
**[[3ene]], [[2v4l]], [[2a4z]], [[2a5u]], [[1e7u]], [[1e7v]], [[1e8w]], [[1e8y]], [[1e8z]], [[1e90]], [[1e8x]], [[3tls]], [[3apc]], [[3apd]], [[3apf]], [[3s2a]], [[3r7q]], [[3r7r]], [[3p2b]], [[3mjw]], [[3nzs]], [[3nzu]], [[3qaq]], [[3qar]], [[3zvv]], [[3zw3]], [[3sd5]], [[3t8m]], [[3tl5]], [[4anu]], [[4anv]], [[4anw]], [[4anx]], [[4aof]], [[4dk5]], [[4f1s]], [[4fa6]], [[4fad]], [[4fhj]], [[4fhk]], [[4fjy]], [[4fjz]], [[4flh]], [[4ful]], [[4g11]], [[4gb9]], [[4hle]], [[4hvb]], [[4j6i]], [[4ps3]], [[4ps7]], [[4ps8]], [[4urk]], [[4wwn]], [[4wwo]], [[4wwp]], [[5t23]], [[5kae]], [[5jhb]], [[5jha]], [[5g55]], [[5g2n]], [[5eds]], [[4xz4]], [[4xx5]] – hTI-PI3K p110γ + inhibitor <br />
+
**[[3ene]], [[2v4l]], [[2a4z]], [[2a5u]], [[1e7u]], [[1e7v]], [[1e8w]], [[1e8y]], [[1e8z]], [[1e90]], [[1e8x]], [[3tls]], [[3apc]], [[3apd]], [[3apf]], [[3s2a]], [[3r7q]], [[3r7r]], [[3p2b]], [[3mjw]], [[3nzs]], [[3nzu]], [[3qaq]], [[3qar]], [[3zvv]], [[3zw3]], [[3sd5]], [[3t8m]], [[3tl5]], [[4anu]], [[4anv]], [[4anw]], [[4anx]], [[4aof]], [[4dk5]], [[4f1s]], [[4fa6]], [[4fad]], [[4fhj]], [[4fhk]], [[4fjy]], [[4fjz]], [[4flh]], [[4ful]], [[4g11]], [[4gb9]], [[4hle]], [[4hvb]], [[4j6i]], [[4ps3]], [[4ps7]], [[4ps8]], [[4urk]], [[4wwn]], [[4wwo]], [[4wwp]], [[5t23]], [[5kae]], [[5jhb]], [[5jha]], [[5g55]], [[5g2n]], [[5eds]], [[4xz4]], [[4xx5]], [[6gq7]] – hTI-PI3K p110γ + inhibitor <br />
**[[3tjp]], [[4ezj]], [[4ezk]], [[4ezl]], [[4kz0]], [[4kzc]] - hTI-PI3K p110γ (mutant) + inhibitor<br />
**[[3tjp]], [[4ezj]], [[4ezk]], [[4ezl]], [[4kz0]], [[4kzc]] - hTI-PI3K p110γ (mutant) + inhibitor<br />
-
**[[3dpd]] – hTI-PI3K p110γ + oxazines inhibitor <br />
+
**[[3dpd]], [[6aud]] – hTI-PI3K p110γ + oxazines inhibitor <br />
-
**[[3dbs ]]– hTI-PI3K p110γ + GDC0941 <br />
+
**[[3dbs]] – hTI-PI3K p110γ + GDC0941 <br />
**[[3csf]], [[3cst]] – hTI-PI3K p110γ + organourethenium inhibitor <br />
**[[3csf]], [[3cst]] – hTI-PI3K p110γ + organourethenium inhibitor <br />
**[[2chw]], [[2chx]], [[2chz]] – hTI-PI3K p110γ + PIK-39 inhibitor<br />
**[[2chw]], [[2chx]], [[2chz]] – hTI-PI3K p110γ + PIK-39 inhibitor<br />

Revision as of 07:32, 21 August 2018

This page, as it appeared on November 15, 2010, was featured in this article in the journal Biochemistry and Molecular Biology Education.

PI3K (grey) complex with NISH2 P85α and wortmannin (PDB code 3hhm)

Drag the structure with the mouse to rotate

3D Structures of PI3K

Updated on 21-August-2018

Additional Resources

  • See: Cancer For Additional Proteins involved in the disease.
  • See: Oncogenes for Additional examples of oncogenes and tumor suppressor genes.


References

  1. Djordjevic S, Driscoll PC. Structural insight into substrate specificity and regulatory mechanisms of phosphoinositide 3-kinases. Trends Biochem Sci. 2002 Aug;27(8):426-32. PMID:12151228
  2. 2.0 2.1 2.2 Wymann MP, Pirola L. Structure and function of phosphoinositide 3-kinases. Biochim Biophys Acta. 1998 Dec 8;1436(1-2):127-50. PMID:9838078
  3. Sasaki T, Irie-Sasaki J, Horie Y, Bachmaier K, Fata JE, Li M, Suzuki A, Bouchard D, Ho A, Redston M, Gallinger S, Khokha R, Mak TW, Hawkins PT, Stephens L, Scherer SW, Tsao M, Penninger JM. Colorectal carcinomas in mice lacking the catalytic subunit of PI(3)Kgamma. Nature. 2000 Aug 24;406(6798):897-902. PMID:10972292 doi:10.1038/35022585
  4. Bi L, Okabe I, Bernard DJ, Wynshaw-Boris A, Nussbaum RL. Proliferative defect and embryonic lethality in mice homozygous for a deletion in the p110alpha subunit of phosphoinositide 3-kinase. J Biol Chem. 1999 Apr 16;274(16):10963-8. PMID:10196176
  5. Miled N, Yan Y, Hon WC, Perisic O, Zvelebil M, Inbar Y, Schneidman-Duhovny D, Wolfson HJ, Backer JM, Williams RL. Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit. Science. 2007 Jul 13;317(5835):239-42. PMID:17626883 doi:317/5835/239
  6. Stephens LR, Hughes KT, Irvine RF. Pathway of phosphatidylinositol(3,4,5)-trisphosphate synthesis in activated neutrophils. Nature. 1991 May 2;351(6321):33-9. PMID:1851250 doi:http://dx.doi.org/10.1038/351033a0
  7. Hoedemaeker FJ, Siegal G, Roe SM, Driscoll PC, Abrahams JP. Crystal structure of the C-terminal SH2 domain of the p85alpha regulatory subunit of phosphoinositide 3-kinase: an SH2 domain mimicking its own substrate. J Mol Biol. 1999 Oct 1;292(4):763-70. PMID:10525402 doi:http://dx.doi.org/10.1006/jmbi.1999.3111
  8. Harris SJ, Foster JG, Ward SG. PI3K isoforms as drug targets in inflammatory diseases: lessons from pharmacological and genetic strategies. Curr Opin Investig Drugs. 2009 Nov;10(11):1151-62. PMID:19876783


Personal tools